Get the Stockscreener App
13.96
7.14%
0.93
After Hours:
13.96
Xencor Inc stock is traded at $13.96, with a volume of 1.05M.
It is up +7.14% in the last 24 hours and up +62.33% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$13.03
Open:
$13.13
24h Volume:
1.05M
Relative Volume:
1.21
Market Cap:
$995.67M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-4.8304
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+18.41%
1M Performance:
+62.33%
6M Performance:
+63.47%
1Y Performance:
-34.43%
1-Day Range:
$13.02
$13.99
1-Week Range:
$11.36
$13.99
52-Week Range:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
13.96 | 929.34M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Reversal indicators forming on Xencor Inc. stock2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Forecasting Xencor Inc. price range with options dataDividend Hike & Technical Buy Zone Confirmation - newser.com
Xencor Inc. stock prediction for this weekEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Can Xencor Inc. stock continue upward trendWeekly Stock Recap & Safe Investment Capital Preservation Plans - newser.com
How to manage a losing position in Xencor Inc.Weekly Volume Report & Community Shared Stock Ideas - newser.com
What MACD and RSI say about Xencor Inc.Portfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
Published on: 2025-10-13 00:04:16 - newser.com
Equities Analysts Issue Forecasts for Xencor FY2025 Earnings - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
How hedge fund analytics apply to Xencor Inc. stockLayoff News & Verified Momentum Stock Alerts - newser.com
How Xencor Inc. stock performs in rising dollar environmentMarket Risk Analysis & Trade Opportunity Analysis Reports - newser.com
What’s next for Xencor Inc. stock priceJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Xencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
What does recent volatility data suggest for Xencor Inc.July 2025 Reactions & Safe Capital Growth Plans - newser.com
Will Xencor Inc. (XE9) stock outperform small cap peersEarnings Overview Summary & Consistent Return Strategy Ideas - newser.com
Is Xencor Inc. (XE9) stock nearing a technical breakoutWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com
Will Xencor Inc. stock maintain momentum in 2025July 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
How to recover losses in Xencor Inc. stockJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Is Xencor Inc. stock recession proofJuly 2025 Rallies & Verified Entry Point Detection - newser.com
Tracking the Evolving Narrative for Xencor After Mixed Analyst Developments - Yahoo
Cantor Fitzgerald Comments on Xencor FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Xencor FY2025 Earnings - MarketBeat
Xencor (NASDAQ:XNCR) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Xencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Market reaction to Xencor Inc.’s recent news2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Relative strength of Xencor Inc. in sector analysisMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Why Xencor Inc. is moving todayLong Setup & AI Forecasted Entry/Exit Points - newser.com
What recovery options are there for Xencor Inc.M&A Rumor & AI Optimized Trade Strategies - newser.com
The Precedent: Federal Circuit Requires Jepson Claim Preambles Satisfy § 112’s Written Description Requirement in In re: Xencor, Inc. - JD Supra
Can machine learning forecast Xencor Inc. recoveryBuy Signal & Risk Controlled Stock Alerts - newser.com
Why Xencor Inc. (XE9) stock attracts wealthy investors2025 Performance Recap & Risk Managed Trade Strategies - newser.com
Should you wait for a breakout in Xencor Inc.Portfolio Performance Report & Reliable Intraday Trade Plans - newser.com
Volume spikes in Xencor Inc. stock – what they mean2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):